Comparative Effectiveness of Dulaglutide, Semaglutide, and Tirzepatide in Preventing Cardiovascular Events in Patients With Type 2 Diabetes and Obesity With or Without Atherosclerotic Cardiovascular Disease.

Registration

Registration

NCT07417618

Acronym

INTERCEPT

Study type

OBSERVATIONAL

Status

COMPLETED

Enrollment

60000

Start

2026-01-27

Primary completion

2026-06-19

Lead sponsor

Brigham and Women's Hospital

Conditions

Type 2 Diabetes; Overweight; ASCVD

Interventions

DRUG:Dulaglutide; DRUG:Semaglutide; DRUG:Tirzepatide; DRUG:Sitagliptin

Results posted

FALSE

Registered primary outcomes

• Composite of myocardial infarction, stroke, or all-cause mortality (with ASCVD) [Through study completion until first of outcome, disenrollment, end of study period, 365 days after cohort entry, discontinuation (45 days grace and risk window), switch between study arms, nursing home admission, or start of any other GLP-1-RA or DPP4i]
• Composite of myocardial infarction, or stroke (with ASCVD) [Through study completion until first of outcome, disenrollment, end of study period, 365 days after cohort entry, discontinuation (45 days grace and risk window), switch between study arms, nursing home admission, or start of any other GLP-1-RA or DPP4i]
• Composite of myocardial infarction, stroke, or all-cause mortality (without ASCVD) [Through study completion until first of outcome, disenrollment, end of study period, 365 days after cohort entry, discontinuation (45 days grace and risk window), switch between study arms, nursing home admission, or start of any other GLP-1-RA or DPP4i]
• Composite of myocardial infarction, or stroke (without ASCVD) [Through study completion until first of outcome, disenrollment, end of study period, 365 days after cohort entry, discontinuation (45 days grace and risk window), switch between study arms, nursing home admission, or start of any other GLP-1-RA or DPP4i]